Device Trial Radar · NCT06615154
The AMBULATE EXPAND Trial: VASCADE MVP XL for Femoral Venous Access Sites, 16-17F OD
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Feb 28, 2025
Primary completion
Aug 18, 2025
Study completion Aug 18, 2025
Sponsor
- Lead sponsor
- Haemonetics CorporationPublic (HAE)
- Sponsor type
- Industry
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-Center, Prospective, Single Arm, Pivotal Trial to Evaluate the Safety and Efficacy of the VASCADE MVP® XL Venous Vascular Closure System (VVCS) for the Management of the Femoral Venotomy After Catheter-Based Interventions Performed Utilizing 16-17F Outer Diameter (OD) Sheaths
Conditions
- Surgical Wound
- Vascular Access
Interventions
VASCADE MVP XL (800-1014XL)Device
VASCADE MVP XL (800-1014XL) used to close the singular femoral venous 16-17F OD access site
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Major Access Site Closure-related ComplicationsTime frame: 30 +/- 7 days post-procedure
- Time to Ambulation (TTA)Time frame: Up to 4 hrs after the procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.